Eton Pharmaceuticals (ETON) said Thursday that the US Food and Drug Administration has extended the review deadline for Eaton's new drug application for ET-400, its proprietary patented formulation of hydrocortisone oral solution.
The new Prescription Drug User Fee Act goal date is May 28.
The FDA informed Eton that more time is needed to review additional information submitted in December. The new deadline reflects a standard three-month extension from the original date of Feb. 28.
"We do not expect this standard extension to significantly affect our internal 2025 revenue projections," Chief Executive Sean Brynjelsen said.
Price: 18.03, Change: -0.23, Percent Change: -1.23
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。